Related Experiment Video
Updated: Dec 25, 2025
07:36
Clinical Application of Intense Pulsed Light Therapy and Radio Frequency for Treatment of Ocular Surface Diseases
Published on: July 3, 2025
514
Refractory palmoplantar pustulosis succesfully treated with apremilast
Raquel Carrascosa de Lome1, Elena Conde Montero1, Pablo de la Cueva Dobao1
1Dermatology Department, Hospital Universitario Infanta Leonor, Madrid, Spain.
Dermatologic Therapy
|January 26, 2020
Summary
Apremilast effectively treated a patient with refractory palmoplantar pustulosis, a chronic inflammatory condition. This case highlights apremilast
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Palmoplantar pustulosis is a chronic inflammatory skin condition causing sterile pustules on hands and feet.
- Apremilast, a phosphodiesterase-4 inhibitor, is approved for plaque psoriasis and psoriatic arthritis.
- Limited data exists on apremilast's efficacy for palmoplantar pustulosis, with no prior clinical trials.
Observation:
- A case of refractory palmoplantar pustulosis is presented.
- The patient's condition did not respond to previous treatments.
Findings:
- Successful treatment of refractory palmoplantar pustulosis with apremilast was observed.
- Apremilast demonstrated significant efficacy in managing the patient's symptoms.
Implications:
- Apremilast may be a viable therapeutic option for palmoplantar pustulosis.
- Further clinical trials are warranted to confirm apremilast's effectiveness in a larger patient cohort.
- This case contributes to the limited evidence base for apremilast in treating palmoplantar pustulosis.
